BioSpace News Archive

Viracta Therapeutics, Inc. today announced that the European Commission (EC) has granted an orphan drug designation (ODD) to Viracta’s all-oral combination product candidate, Nana-val (nanatinostat and valganciclovir), for the treatment of diffuse large B-cell lymphoma (DLBCL).

Nova Graphene Ballistics, Inc. (OTC PINK: BIEI), (“pending the name change from “Premier Biomedical Inc.”), announces the following steps, in pursuit of its first initiative 3D-printed Graphene Ballistic Plate Production, including the prototype, with regard to novel graphene production.

Celsius Therapeutics today announced that new data on CEL383, a potential first-in-class anti-TREM1 antibody for the treatment of inflammatory bowel disease (IBD), has been selected for oral presentation at the 6th Annual Crohn’s & Colitis Congress, taking place January 19-21, 2023, in Denver, Colorado.

Surmodics, Inc. today announced that the differentiated capabilities of its crystalline drug release (CDR) platform for sirolimus-coated balloons (SCBs) were discussed in connection with 12-month data from the Company’s SWING trial at the 35th annual International Symposium on Endovascular Therapy (ISET) in Miami, Florida.

PreciseDx, a leading innovator in AI-powered, patient-specific disease analysis, today announced its recent publication in Breast Cancer Research, demonstrating the ability of its digital AI platform to enrich breast cancer grading and improve risk categorization.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced final results from a biomarker study conducted to evaluate the potential of NeuroSense’s combination platform therapy for the treatment of Alzheimer’s disease (AD).

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the Virtual Q1 Investor Summit Microcap Event.

Linnaeus Therapeutics, Inc. (Linnaeus) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for LNS8801 for the treatment of patients with metastatic cutaneous melanoma.

Dr. Hila Elinav burst into tears of joy when the Israeli Ministry of Health announced a sweeping new HIV screening policy for pregnant women in September.

Astellas Pharma today will present detailed results from the Phase 3 SPOTLIGHT trial evaluating first-line treatment with zolbetuximab.